Decision Support System
Protocol options ranked by Expected Trial Success with full explainability
12
Active Decisions
+18%
Avg Success Improvement
234
Decisions Informed
45
Reports Generated
Protocol Recommendations - NCT-2024-045
1
Biomarker-Stratified Protocol (Recommended)
RecommendedHigh Confidence
Success Probability
54%
Sample Size
n=342
Duration
24mo
Est. Cost
$12.8M
Key Changes:
Restrict enrollment to Biomarker-Positive Group A
Add biomarker screening at enrollment
Reduce sample size from 833 to 342
Advantages
- •22% increase in success probability
- •59% reduction in sample size
- •Better ROI
Tradeoffs
- •Extended enrollment timeline (+6 months)
- •Higher screening costs
2
Modified Inclusion Criteria
Medium Confidence
Success Probability
48%
Sample Size
n=556
Duration
21mo
Est. Cost
$15.2M
Key Changes:
Narrow age range to 45-65 years
Require ECOG 0-1 only
Moderate sample size reduction
Advantages
- •16% increase in success probability
- •Faster enrollment
- •Lower screening costs
Tradeoffs
- •Moderate sample size reduction only
- •Still heterogeneous population
3
Current Protocol (Baseline)
High Confidence
Success Probability
32%
Sample Size
n=833
Duration
18mo
Est. Cost
$18.5M
Advantages
- •Broadest patient pool
- •Fastest enrollment timeline
Tradeoffs
- •Low success probability
- •High failure risk
- •Highest cost
Other Pending Decisions
Dose Selection for Phase III
NCT-2024-0383 options analyzedDeadline: 2 weeks
High
Interim Analysis Timing
NCT-2024-0612 options analyzedDeadline: 1 month
Medium
Adaptive Design Implementation
NCT-2024-0524 options analyzedDeadline: 1 week
High